• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Rapport Therapeutics (RAPP) On Fresh Funding And Phase 2 Progress Has Valuation Back In Focus

    Simply Wall St·10/31/2026 05:41:57
    Listen to the news

    Rapport Therapeutics (RAPP) is back in focus after lining up fresh funding alongside new clinical data. The company just completed a roughly $200 million follow on equity raise and a $150 million convertible notes offering.

    Rapport Therapeutics’ recent funding moves come after a sharp re-rating in the shares. The 30-day share price return is down 25.48%, and the 90-day move is weaker at 38.90%, despite a 3.43% gain in the latest session to US$25.04.

    Capitalize on the funding momentum around Rapport Therapeutics by scanning a curated 18 high quality undiscovered gems that could be running similar under-the-radar clinical or financing stories.

    Fresh capital in the door and a stock that has slid sharply in recent months set up a simple tension for Rapport Therapeutics. Do current levels still compensate you for the clinical and financing risks on the table?

    Most Popular Narrative: 64% Undervalued

    Analysts following Rapport Therapeutics see a fair value of about $69 per share against the latest close at $25.04. This valuation places significant emphasis on RAP-219 and the broader precision neuroscience platform to narrow that gap.

    Application of Rapport Therapeutics’ receptor associated protein and ion channel platform into new indications such as pain, migraine and vestibular disorders, enabled by existing CNS biology and early programs like the planned Phase I α6β4 study, offers multiple shots on goal that could diversify future revenue and reduce dependence on a single product for earnings.

    See why 1 investors see Rapport Therapeutics as 64% undervalued.

    Result: Fair Value of $69.06 (UNDERVALUED)

    Still, the RAP-219 epilepsy and bipolar mania program carries clear risk, and any funding shortfall or safety setback could rapidly challenge the current undervalued narrative on Rapport Therapeutics.

    Find out about the key risks to this Rapport Therapeutics narrative.

    Next Steps

    Mixed signals around Rapport Therapeutics can make the story feel messy, so move quickly, review both sides of the ledger, then weigh the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Rapport Therapeutics?

    Do not stop your research at one clinical-stage story. Cast a wider net with a few focused stock lists that can surface fresh opportunities quickly.